Serum ACE
[Serum ACE]
EPTIS factsheet 142643 | Last revision 2024-05-21 | URL: https://www.eptis.bam.de/pts142643 https://www.eptis.bam.de/pts142643
| PT provider | |||||||
| PT provider | Weqas Weqas | ||||||
| Based in | United Kingdom | ||||||
| Language(s) | |||||||
| Remarks | ACE (angiotensin I converting enzyme) is as a key component of the renin-angiotensin system, whose main function is to process angiotensin I to angiotensin II and degrade bradykinin. The renin-angiotensin system is responsible for the maintenance of normal blood pressure and electrolyte balance. ACE is expressed in endothelial and epithelial cells and is found in arterioles, muscular arteries and capillaries in the lungs, as well as the kidney. Three liquid human serum samples are distributed bimonthly, with a minimum of 18 samples distributed over the year covering a wide, clinically relevant range. A panel of 7 samples are produced from blood donations from healthy volunteers and patients to cover the normal and pathological clinical range. Four of the pools are distributed 3 times and 3 pools distributed twice. The programme assesses both laboratory and method performance, including bias, within and between batch imprecision and linearity. Key Features: - Liquid human serum samples require no pre-analytical preparation. - Endogenous samples commutable across all testing platforms. - Pathological range covered. - Scoring based on Milan Model 3 performance specification. - Each donation is distributed on a number of occasions over the year to assess both laboratory and method performance, including bias, within and between batch imprecision. For more information: https://www.weqas.com/services/eqa/serumace/ or contact@weqas.com | ||||||
| Keywords | |||||||
| Product groups |
Health care / medical devices
|
||||||
| Testing fields |
Medical analysis
|
||||||
| Technical details | |||||||
|
|||||||
| Aims of the PT scheme | |||||||
| Target group of participants | The programme assesses both laboratory and method performance, including bias, within and between batch imprecision and linearity. | ||||||
| Linked to specific legislation / standards | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Additional, subsidiary aims | validation of testing methods | ||||||
| Number of participants | |||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
||||||
| Operation is commissioned / requested by | |||||||
| Fees and frequency | |||||||
| Participation fee | Fee dependent on number of participating sections and proximetry of testing methods. | ||||||
| Regularly operated | Yes (Frequency: Bimonthly. Samples: 3 x 0.5mL) | ||||||
| Year of first operation | 2010 | ||||||
| Contact details of the PT provider | |||||||
| Provider | Contact person | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.